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ABSTRACT: Drug screening for antimalarials uses heme
biocrystallization inhibition methods as an alternative to
parasite cultures, but they involve complex processes and
cannot detect artemisinin-like molecules. The described
method detects heme-binding compounds by mass spectrom-
etry, using dissociation of the drug−heme adducts to evaluate
putative antiplasmodial activity. Applied to a chemical library,
it showed a good hit-to-lead ratio and is an efficient early stage
screening for complex mixtures like natural extracts.
Malaria is a recurring challenge for health policies,medicinal research, and the pharmaceutical industry.
This potentially lethal infection is vector-borne and thrives in
tropical areas that are often highly populated by low-income
communities resulting in the endemic exposure of 3 billion
people to the various species and strains of Plasmodium. The
fact that most of the drugs currently used to cure or prevent
malaria have been known and used for decades (if not
centuries) also contributes to the critical situation in terms of
resistance. The emerging resistance to artemisinine analogs is of
primary concern. Antimalarial drug discovery can follow two
approaches. Assays performed on whole parasite in living
erythrocytes have the advantage of allowing the discovery of
drugs acting on unidentified targets but imply the use of blood
of human or animal origin, along with handling of live, infective
parasites.1 Target-based approaches require much simpler
equipment. One of the most studied and most promising
targets in malaria is the strictly parasite-specific, heme
detoxification pathway. The massive release of free, toxic
ferriprotoporphyrin IX is handled by the parasite via its
biomineralization into hemozoin, a supramolecular assembly of
heme dimers (Figure 1).2,3 As it is not protein dependent, there
is no possibility of resistance against this target per se by
genotypic mutation or phenotypic overexpression. Conse-
quently, the inhibition of synthetic hemozoin formation (called
β-hematin) is the basis for a variety of tests aimed at the
discovery of antimalarial compounds.4 Noteworthy, the
hemozoin pathway can also be considered as a target for
antischistosomal compounds.5
The use of mass spectrometry to confirm and characterize
complexes between small molecules and Fe(III) heme has been
used by several authors.6−10 Some of these authors used
collision-induced dissociation (CID) to assess the strength of
the association between Fe(III) heme and drugs. In the present
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Figure 1. Hemozoin formation pathway.
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work, we validate and implement this approach for a complex
mixture. A chemical library has also been screened to
demonstrate it can be used as a screening tool, especially for
natural products and extracts. We also set up a protocol
identifying compounds that form a covalent bond with Fe(II)
heme, providing an original screening tool able to detect
artemisinine-like compounds.
■ EXPERIMENTAL METHODS
Hemin, the ferriprotoporphyrin used for the incubation, gave
several molecular ions in the simple quadrupole instrument,
namely, [Heme]+ at m/z 616.2 and heme dimers at m/z 1232.3
([2Heme]+) and m/z 1253.3 ([2Heme + Na]+). The
characteristic isotopic pattern of heme (mainly, M + 1 for
39.6% along with M + 2 for 9.2%) makes the signal of any
species containing heme clearly identifiable. Heme is detected
at its native mass although the iron is in the Fe(III) form, as it is
complexed by the porphyrin nitrogens. Consequently, Fe(II)
heme is not detected by MS. Heme dimers were observed in
the triple quadrupole spectra except the dimer-sodium adducts.
The specificity of the method, i.e., its ability to detect heme-
targeting entities, was validated on a set of compounds showing
antimalarial activity, acting by heme disposal interference
(positive controls) or by other mechanisms (negative controls).
Adducts were obtained with a large set of antimalarial drugs
tested (Table 1 in Supporting Information). In addition to the
identification of adducts, a relative indication of the strength of
the binding between two components of a complex can be
obtained by mass spectrometry. Indeed, in a single quadrupole,
the parameter called fragmentor voltage is the transfer voltage
applied between the end of the transfer capillary and the first
skimmer placed in front of the focusing octopole and the
quadrupole analyzer. The higher the voltage, the faster ions are
accelerated and the higher the energy of subsequent
intermolecular collisions. In such an instrument, fragmentor
voltage also impacts the ion transfer. As a consequence, for a
given species subjected to fragmentor variations, abundance
variations are the result of transfer variations as well as
fragmentation if any. To account for these effects, we recorded
the abundance of heme depending on the fragmentor voltage,
using a flow injection analysis mode consisting of repeated
sample injections at increasing fragmentor voltage, ranging
from 130 to 400 V with 30 V increments. Abundance intensities
were recorded and plotted as a function of fragmentor voltage,
the maximum abundance being normalized at 100%. The
fragmentor voltage determining 50% of the dissociation is
noted as DV50.
A fragmentor increase in simple quadrupole instrument
causes a decrease of heme abundance signal, until a
reproducible plateau of 41% that can be considered as the
amount of heme molecule resistant to fragmentation and
enventually transferred to the analyzer (Figure 2). Indeed, in
such collision-induced dissociation (CID) experiments, intra-
molecular fragmentations are less likely to appear, as they
require more energy and as the ESI mode used in these
experiments are designed to prevent molecular fragmentation.
In the triple quadrupole instrument, the acceleration is
performed by the second quadrupole and collisions with the
inert gas are much more energetic, finally leading to a complete
disappearance of the heme signal without any plateau.
■ RESULTS
CID experiments were performed for heme−drug adducts, and
examples of curves are given in Figure 3 (curve data are
summarized in Table 1 of Supporting Information). Com-
pounds like quinolines, artemisinine,11,2 azoles,12,13 halofan-
trine, and pyronaridine are well documented for acting via a
heme-interacting mechanism.
Among quinolines, only amodiaquine and piperaquine show
a significantly different curve than every other quinoline.
Although the DV50 is similar, a significant amount of complex
(ca 8%) remains present even for higher fragmentor voltages.
This can be interpreted as the consequence of a particularly
strong binding between amodiaquine and heme. Among
quinolines, amodiaquine shows enhanced activity, parasite-
specific accumulation, and decreased cross-resistance pattern in
vitro. Its structure comprises p-hydroxyaniline aromatic ring,
substituted at 5′ with an alkylamine, and has been under focus
Figure 2. Stability curves of heme (m/z = 616) obtained by CID
experiments in simple quadrupole and triple quadrupole instrument
(fragmentor conditions: see text).
Figure 3. Amodiaquine metabolism providing a quinone-imine.
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of several structure−activity relationship (SAR) studies. Studies
on the interaction of amodiaquine and heme have demon-
strated that the aromatic ring increases lipophilicity and side
chain rigidity, thus favoring π−π stacking interactions (ref 14
and references cited therein). Moreover, the 5′ position allows
modulation of the lipophilicity, having a significant effect on
activity and cross-resistance. The importance for the high
activity of amodiaquine of the 4′-hydroxy group involved in a
Mannich-base pattern is controversial but does not seem to be
crucial for activity, as 4′-dehydroxy amodiaquine maintains and
even shows higher antimalarial activity. Noteworthy, pyronar-
idine also contains a Mannich base pattern, but it is hindered by
two adjacent pyrrolidine, explaining its lower reactivity.
However, it has been shown to be a substrate of oxidation by
cytochromes P450 leading to a quinone-imine, an electrophilic
metabolite susceptible to bind to proteins and contributes to its
toxicity (Figure 3).14
These data corroborate our findings, suggesting a particularly
strong interaction between amodiaquine and heme that could
be constituted by a covalent bound. Traditional β-hematin
inhibition assays comparing chloroquine and amodiaquine do
not indicate a higher β-hematin polymerization inhibition by
amodiaquine, whereas it has a significantly higher activity in
vitro and in vivo. Thus, besides its ability to evaluate the heme−
drug complex binding strength, our method may be a more
relevant tool to screen rapidly for putative activity of molecules.
On the other hand, piperaquine does not present any group
susceptible to form covalent bounds, but its lipophilicity is
significantly higher than other quinolines (log P = 6.79 vs 3 to 5
range, respectively). Such hydrophobicity may explain a strong
hydrophobic interaction between piperaquine and heme. As far
as the DV50 value of curves is concerned, it can be considered as
an indication of the relative affinity toward heme, putatively
correlated to the ability of drugs to inhibit β-hematin formation.
Indeed, within the quinoline group, the relative ranking of drug
affinities for heme in our method is consistent with the IC50
ranking obtained with β-hematin inhibition methods as
reported in the literature15 (when available from one
homogeneous experiment set), namely, amodiaquine >
quinidine > cinchonidine > mefloquine.
Antifungal azoles are known to exert their antimalarial
activity through inhibition of hemozoin formation.13 Hybrid
drugs combining 4-aminoquinoline- and clotrimazole-based
pharmacophores have been synthesized and showed higher β-
hematin polymerization inhibition than chloroquine or
clotrimazole by themselves.16 As expected, every azole tested
in the present method formed an adduct with heme.
Relative stabilities of heme−drug adducts showed significant
differences between tested azoles. When considering DV50 as a
relative indication of stability, complex stability can be ranked
by increasing stability as miconazole < clotrimazole <
ketoconazole. This is in accordance with data of IC50 for β-
hematin polymerization inhibition reported by Chong et al.,12
namely, ketoconazole > clotrimazole > miconazole. Binding of
heme with azoles was suggested in our method to be stronger
than with quinolines, which is not in accordance with the
biological activities for the azole series. This may be explained
by lipophilicity characteristics and pKa values that may reduce
the ability of the drug to reach the digestive vacuole, as well as
the accumulation phenomenon within it, which is partly
responsible for the high activity of some quinolines.
Antibiotics like doxycycline and clindamycin are good
candidates for combined antimalarial therapies because of
their delayed parasiticidal action on the apicoplast.17 Biguanide
derivatives (proguanil, metformine, and phenformine) are used
as antimalarial or antihyperglycemic agents, but the mechanism
of antimalarial action is still unclear and hypothesized to be a
dihydrofolate reductase inhibition, along with a protease
inhibition and the mitochondrial complex I inhibition. Cyclines
and biguanides have not been described as drugs inhibiting β-
hematin polymerization, but most of them have never been
assessed for such activity. Nevertheless, one common feature of
these molecules may be their binding to endogenous metals,
e.g., Zn2+, Cu2+, and Fe3+ 18,19 that can explain the formation of
adducts with heme in our protocol.
Other therapeutical classes are known to possess antimalarial
activity without being described inhibitors of β-hematin
formation: among them, antifolates (pyrimethamine, sulfadox-
ine) act by interfering with the folate metabolism essential to
the parasite.20 Triclosan, a chlorinated antiseptic, interferes with
the parasite-specific fatty acid synthesis in the apicoplast, along
with other mechanisms of action.21 Dinitroaniline antimitotic
herbicides (trifluralin, oryzalin) target the parasite-specific
region of tubulin and showed antimalarial activity and no
mammalian cell toxicity.22 When these compounds were
incubated with heme, no adduct or adducts of very weak
stability (DV50 < 200 V, see below) were observed. For example
an adduct was observed for sulfadoxine which contains a sulfur
atom that may explain some affinity with heme. Indeed, sulfur
and iron are known to form clusters, and most of the
mitochondrial electron transport enzymes are based on iron−
sulfur clusters.23 Adduct with pyrimethamin may be based on
the ability of the diaminopyrimidine group to interact with
heme in a coordination mode.
Artemisinin and its derivatives are known to act by alkylating
heme and proteins following a chemical change catalyzed by
Fe(II) heme. As demonstrated by Robert et al.,24 the reductive
activation of endoperoxide by Fe(II) heme produces the
homolytic cleavage of the endoperoxide bond and the
subsequent formation of drug-derived C-centered radicals,
able to alkylate heme or other proteins. The covalent binding of
artemisinin to heme is a determining element explaining its
significant activity.
In order to specifically identify compounds acting like
artemisinin, an incubation was performed with Fe(II) heme
generated in situ by adding glutathione 2.5 mM in the
incubation mixture as described by Robert et al.24 Such
conditions reproduce the content of the erythrocyte where the
high concentration of this mild reducing agent devoted to
protect parasite from oxidative stress (redox milieu −250 mV)
contributes to prevent Fe(II) heme oxidation. In our method,
artifacts specific to these reductive conditions could be
observed in the spectra, mostly species at m/z 613 [glutathione
oxidized dimers]+ and m/z 694.2 [heme + DMSO]+. The
absence of signal at m/z 616.2 confirmed the complete
reduction of heme into its Fe(II) form, as Fe(II) heme does not
ionize in this ionization source. When artemisinin is incubated
with Fe(III) heme, our method shows that the adduct formed
by artemisinin is weaker than the heme−quinolines adducts
(DV50 160 V and 170−204 V range, respectively). However,
when incubated under reductive conditions and therefore with
Fe(II) heme, artemisinin forms an adduct of higher affinity
(DV50 177 V) and is resistant to fragmentation even at high
voltage, as can be seen on the plateau of 36.5%, suggesting an
adduct as stable as hemin itself (see Figure 4). Such a pattern is
consistent with the covalent nature of the binding between
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heme and artemisinin. The covalent nature of the binding
between the adducts of artemisinin with Fe(II) heme was
confirmed by the appearance in the spectrum of the species at
m/z 898.5 but also at m/z 870.4, m/z 855.4, and m/z 838.4,
resulting from fragmentations specific to the covalent adduct as
reported by Accardo et al.25
Triple quadrupole CID experiments corroborated these
observations. Indeed, the decreasing signal at m/z 898
corresponding to artemisinin-Fe(II) heme could be correlated
with the increasing signal at m/z 838, corresponding to the loss
of [CH2 − COOH + H]+ as was reported by Robert et al.,
24
thus confirming the stable bound between artemisinin and
heme (Figure 5)
The ability of the method to detect adduct-forming
compounds in complex mixtures was assessed by incubating
Fe(III) heme with natural extracts, namely, Cinchona bark
alkaloidic extract and Artemisia extract. Cinchona alkaloidic
extract contains a mixture of naturally occurring quinoline
alkaloids in various proportions, mainly, quinine, quinidine,
cinchonine, and cinchonidine along with other secondary
metabolites. Mass spectra of heme−Cinchona showed peaks at
m/z 295.0 ([cinchonine/cinchonidine + H]+) and m/z 325.0
([quinine/quinidine]+) and adducts at m/z 910.3 ([cincho-
nine/cinchonidine + heme]+) and m/z 940.3 ([quinine/
quinidine + heme]+) (See Figure 2A in Supporting
Information). Artemisia cyclohexane extract shows greater
complexity, but mass spectra of heme−Artemisia showed
peaks of artemisinin−heme adducts fragments at m/z 870.4
and 855.4 (See Figure 2B in Supporting Information).
Noteworthy, the stability curve of artemisinin−Fe(II) heme
adducts can be obtained from adduct detected in the extract
and is similar to the curve obtained with artemisinin standard
(data not shown). The method is therefore able to specifically
detect antimalarial compounds based on a covalent interaction,
which is a major factor of clinical efficacy.
■ DISCUSSION
Currently, a dozen of antimalarial molecules only are in the
development stage out of the >5 millions compounds screened
so far in various programs. Such an attrition rate highlights the
need of high-throughput techniques for antimalarial drug
discovery. Beyond this prerequisite, the path to such
compounds can follow two approaches.4
Assays performed on whole parasite in living erythrocytes
have the advantage of allowing the discovery of drugs acting on
unidentified targets and are favored by companies. Several
monitoring strategies are used to measure parasite replication in
red blood cells. The most sensitive method is based on the
incorporation of 3H-hypoxanthine by the parasite. Radioactivity
handling is renowned to be expensive (probe purchasing and
disposal) and uprises safety and environmental concerns.
Parasites can alternatively be labeled by fluorescent probes
and counted by flow cytometry. These dyes are mutagenic and
cause low signal-to-noise ratios due to their binding to
exogenous (human) DNA. Colorimetric monitoring is possible
but requires many steps and expensive reagents. Transgenic
parasites allow luminescence assays (through transfected
luciferase), but these strains still carry drug selectable markers,
which might interfere with the drug screening process. Some of
these tests can be performed in microplates, but none seem to
have been used in a high-throughput screening (HTS)
campaign. In all cases, culture is performed in red blood cells,
implying the use of blood of human or animal origin, along
with alive, infective parasites handling.
Figure 4. Stability curves obtained by CID experiments performed on
the different heme−drug complexes. Fragmentor values range from
130 (x = 1) to 400 V (x = 10) with 30 V increments. Adducts
observed for pure standard drugs and Fe(III) heme if not otherwise
stated.
Figure 5. Effect of fragmentor voltage in triple quadrupole MS2 on
abundances of artemisinine−heme adduct and fragments thereof
(experimental conditions: see text).
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Target-based approaches require much simpler equipment.
The hemozoin formation pathway is a major target, and efforts
to reproduce heme crystallization outside the parasite have led
to a vast literature. Dimers associate in a crystal called β-
hematin, which is identical to hemozoin (Figure 1). This
phenomenon requires time (usually 12 h) but can be
accelerated by the addition of parasite lysate or acetonitrile,
lipidic extracts, corroborating the hypothesis of a determining
role of lipids in β-hematin nucleation. The inhibition of β-
hematin formation by a molecule is interpreted as a direct
indication of its antimalarial activity. Inhibition can be
quantified in several ways. Most of them require the separation
of crystallized β-hematin from hematin monomers and
amorphous aggregates, followed by monitoring of 14C-hematin
incorporation into β-hematin or spectrophotometric measure-
ment of free hematin absorbance after β-hematin dissolution,
sometimes following pyridine addition.
The β-hematin test has been implemented to HTS format. In
such approach, the hit yield depends on the nature of the
library and cannot be used to evaluate the method efficiency to
detect antimalarial compounds. Instead, the hit-to-lead ratio
between the number of hits detected in the screening and the
number of compounds actually validated as antimalarials by the
subsequent in vitro parasite growth test is of significant value. A
low hit-to-lead ratio reflects a significant amount of false
positives. In two reported HTS campaigns, one using parasite-
derived reagents and radiolabeled hematin,26 another using the
pyridine-spectrophotometric method,27 the hit-to-lead ratio was
around 9% (100 000 compounds, active hit defined by an IC50
> 5 μM) and 3% (16 000 compounds, active hit defined by an
IC50 > 20 μM), respectively.
Besides their poor hit-to-lead ratio, a salient feature of tests
based on β-hematin formation is that heme must have the ferric
state (Fe(III) heme). Indeed, no β-hematin formation occurs
with the Fe(II) heme or in the presence of reducing
agents.4,28,29 Therefore, the mechanism of action of artemisi-
nine, the most active current antimalarial, does not take place in
such conditions, and assays based on β-hematin formation
cannot detect artemisinin-like compounds. As a matter of fact,
the antimalarial activity of artemisinin has been discovered
empirically through the traditional use of Artemisia annua by
Chinese herbalists. Its modern use as a pure compound had to
wait a thousand years before being pointed out by Chinese
researchers focusing on the antimalarial activity of the plant.
Other screening tests have been developed, on the basis of
other heme detoxication pathways, but do not have the ability
to detect artemisinin.30
Finally, the β-hematin assay does not provide any
information on the structure of a compound showing
inhibition. This means that, if an active compound contains
impurities or if it is a complex mixture, it has to be either
purified or processed by the so-called bioguided fractionation.
For natural extracts, this implies the tedious isolation of the
active compound and the risk of activity loss along with extract
fractionation. However, the potential of biodiversity for malaria
drug discovery is obvious.31−36 The huge extracts libraries
available in companies or academic institutions require an
access to HTS techniques but are renowned to be very difficult
to handle in such approaches.37 Strategies combining HTS and
techniques providing data simultaneously on activity and
structures are still lacking.
The present method may be of significant interest for such
research areas. Its application to an automatized, miniaturized
pilot test was performed to assess its potential for HTS
screening. Two 96-well plates totaling 172 compounds were
tested out of our in-house library, consisting of pure
compounds of natural or synthetic origin stored in a
randomized order. Among these compounds, 18 were identified
as forming adduct with heme. With the exception of one
compound not tested for technical reasons, these compounds
were tested on two Plasmodium strains, to assess growth
inhibition. Among these compounds, 13 caused over 50%
inhibition at 10 μM on the chloroquine-sensitive F32 strain and
8 caused over 50% inhibition at 10 μM on the K1 chloroquine-
resistant strain. The hit-to-lead ratio can therefore be calculated
as 76% and 47%, respectively. Although these data have to be
confirmed on a larger scale, the MS-based antiplasmodial
screening shows promising to efficiently point out relevant
compounds for further in vitro testing.
■ CONCLUSIONS
We developed a method based on mass spectrometry to detect
and characterize compounds able to bind heme. As usual,
screening tools based on β-hematin crystallization inhibition,
the proposed screening method, is not devoted to directly
correlate to an activity in vivo but is based on the interaction of
small molecules with heme which is the main mechanism of
action of most efficient known atimalarials. The method is
consistent with literature data gathered for β-hematin
inhibition. Validation on a serial of antimalarial drugs suggests
that it can assess the binding strength between heme and
molecule. It can specifically indicate the type of binding
involved, allowing one to especially to detect artemisinin-like
compounds. The artemisinin mechanism based on covalent
binding to heme has proven to be highly effective to cure
malaria, but rising resistance to artemisinin may require one to
orient drug discovery to find structures differing significantly
from artemisinin but based on the same mechanism of action.
The present method fulfills this need and may be therefore of
great interest in malaria drug discovery. The method is
particularly interesting for screening purposes, as it has proved
to be transferable to a HTS scale. Furthermore, it is worth
noting that current assays based on β-hematin polymerization
inhibition do not provide any information on the structure of a
hit. The present method can detect a heme-binding compound
within a complex mixture and simultaneously give structural
information on the compound, opening the path for biological
dereplication of natural extracts.
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